Synlogic (SYBX)
(Delayed Data from NSDQ)
$1.51 USD
-0.04 (-2.58%)
Updated Sep 25, 2024 03:56 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Brokerage Reports
Synlogic, Inc. [SYBX]
Reports for Purchase
Showing records 1 - 20 ( 111 total )
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; With Synpheny-3 Discontinued, Search For Strategic Options Continues; Adjusting Rating to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Synlogic Suffers a Sudden and Stunning Implosion; Downgrade to Sell; Remove PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Synpheny-3 Top-line Data Readout On Target in 1H25; Next Milestone is DMC''s Interim Review in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Synpheny-3 Labafenogene Marselecobac (SYNB1934) PKU Pivotal Study Topline Expected in 1H25; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Publication Shows Labafenogene Marselecobac''s Effects in PKU; New $24 PT With Reverse Split and Equity Raise; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Pivotal Phase 3 Synpheny-3 PKU Study of Labafenogene Marselecobac (SYNB1934) Underway; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Labafenogene Marselecobac''s Fast Track Designation Reflects FDA''s View on PKU As an Urgent Unmet Need
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Synpheny-3 PKU Study Begins; Prioritizing Resources For Advanced Clinical Programs; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
We Do Not Expect Sepiapterin''s Phase 3 APHENITY Trial Results to Affect SYNB1934''s PKU Opportunity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: SYNB1934 Phase 3 PKU Study Initiation on Target in 2Q23; SYNB1353 Enters Phase 2 For HCU in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Novel Platform Technology Engineers Oral Therapies for Multiple Shots on Goal; Assume Buy, $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Third Dataset in 2023-Positive Enteric Hyperoxaluria Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
SYNB1353 Phase 1 Data Supports Proof-of-Mechanism in HCU; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Two Datasets by YE22; PKU Phase 3 in 1H23; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 2 PKU Data Poises SYNB1934 for Pivotal Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biotic Discovery Triggers Roche Milestone Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Three Data Readouts in 2H22; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Subject Dosing Initiated in SYNB1353 Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Three Data Readouts in 2H22; 1Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R